NeonMind Biosciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Penny Olga White BA, LLB
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 295 Robinson Street Oakville ON Canada L6J 1G7
- IPO Date
- Feb 18, 2021
- Website
- neonmindbiosciences.com
- Similar Companies
- Business
- NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) develops and commercializes psychedelic-based therapies and wellness products targeting mental health disorders, obesity, and weight management. The company operates three divisions offering psilocybin-based drug candidates including NEO-001, a high-dose psilocybin agonist for the serotonin 5-HT2A receptor to induce neuroplasticity, and a low-dose program targeting the 5-HT2C receptor for appetite control; specialty mental health clinics providing ketamine and esketamine treatments for mood and anxiety disorders with plans to integrate approved psychedelics; and consumer products such as mushroom-infused coffees featuring lion's mane, turkey tail, reishi, and cordyceps, alongside planned dietary supplements. Founded in 2020 and headquartered in Vancouver, British Columbia, with operations and a new headquarters in Oakville, Ontario to support clinic expansion, NeonMind serves Canadian markets primarily and targets the global weight management sector projected to reach $326 billion by 2028. Recent developments include partnerships with SRx Health and BioScript Solutions to access over 100 clinic locations and launch its inaugural NeonMind-branded facility in Mississauga, Ontario; engagement with the US FDA yielding positive pre-IND feedback for obesity clinical trials; patent pendings with the USPTO for its novel psilocybin programs; a decision to seek a buyer for the NEO-001 asset amid strategic shifts; engagement of Thrive Health for digital patient care; establishment of an R&D advisory board with Philippe Martin; and a 1-for-30 reverse stock split in January 2023.
NeonMind to Present at H.C. Wainwright Bioconnect Conference
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
NeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
NeonMind Advances Strategy for Specialty Clinic Launch
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NeonMind Announces DTC Eligibility
NeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend'
NeonMind Announces Corporate Update and Strategic Reorganization of its Pharmaceutical Division
Dr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory Board
NeonMind Announces Launch of Functional Mushroom Coffees as Dietary Supplements in the US
NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products